For additional information, please contact the BMS oncology clinical trial information
service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit
www.BMSStudyConnect.com for more information on clinical trial participation.

Inclusion Criteria:

- Histologically or cytologically documented NSCLC who present with stage IIIB without
indications for definitive radiotherapy or stage IV or recurrent

- No prior chemotherapy, hormonal therapy, immunotherapy and targeted therapy
containing regimens for the treatment of NSCLC

- Life expectancy of at least 3 months

- Eastern Cooperative Oncology Group performance 0-1

Exclusion Criteria:

- Symptomatic central nervous system (CNS) metastasis, or active CNS metastasis
requiring medication.

- Malignant body cavity fluid (e.g. pleural effusion, cardiac effusion, ascites) that
is recurrent despite appropriate supportive care.

- Autoimmune disease: subjects with a documented history of severe autoimmune or immune
mediated symptomatic disease that required prolonged (more than 2 months) systemic
immunosuppressant treatment